Previous Close | 1.0020 |
Open | 0.9980 |
Bid | 0.9950 x 25000 |
Ask | 1.0800 x 25000 |
Day's Range | 0.9950 - 0.9980 |
52 Week Range | 0.8780 - 1.9060 |
Volume | |
Avg. Volume | 161 |
Market Cap | 33.58M |
Beta (5Y Monthly) | -0.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
PARIS, May 07, 2024--Regulatory News: ABIONYX Pharma (Paris:ABNX):
TOULOUSE, France & LAKELAND, Mich., May 02, 2024--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that it has filed with the "Autorité des Marchés Financiers" (AMF) its Universal Registration Document for the year ended December 31, 2023, dated April 30, 2024.
TOULOUSE, France & LAKELAND, Mich., March 14, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces a nearly €1 million innovation grant from Bpifrance. The aim of this grant is to support the development of drug candidate CER-001 in the treatment of a severe indication in ophthalmology.